Baidu
map

CRT-D术中突发心衰 患者九死一生多亏……

2017-12-14 韩雅玲 王祖禄 朱鲜阳 规避陷阱:心血管疾病介入并发症防治攻略

62岁男性患者,2016年1月因“发作性胸痛3个月,胸闷、气短1周”入院。3个月前外院诊断为急性广泛前壁心肌梗死,心电图示三度房室传导阻滞。预备行CRT-D时,患者突发急性左心竭,经20分钟抢救,患者好转。CRT患者术前需做哪些准备?术中突发紧急情况怎样处理?术后有什么注意事项? 详见以下病例——

62岁男性患者,2016年1月因“发作性胸痛3个月,胸闷、气短1周”入院。3个月前外院诊断为急性广泛前壁心肌梗死,心电图示三度房室传导阻滞。预备行CRT-D时,患者突发急性左心竭,经20分钟抢救,患者好转。CRT患者术前需做哪些准备?术中突发紧急情况怎样处理?术后有什么注意事项? 详见以下病例——

入院1周前患者受凉致上呼吸道感染后出现胸闷、气短、呼吸困难,药物治疗效果不明显。心脏彩色多普勒提示全心增大,心功能减低,室壁运动普遍减弱,左室射血分数0.34。心电图:三度房室传导阻滞。入院后给予优化的药物治疗后,拟行CRT-D。顺序植入左室电极,右室、右房电极并连接脉冲发生器,此时患者突然出现咳嗽、咳白痰,迅速进展至呼吸困难,咳粉红色泡沫痰。心电监测提示:血压:130~140/70~80mmHg,指脉氧饱和度波动85%~90%,双肺可闻及明显干湿啰音,血氧持续下降。考虑患者急性左心心力衰竭发作,立即将患者上身抬起至坐位,保护术区,给予高流量面罩吸氧、呋塞米60mg静推利尿、去乙酰毛花苷注射液0.2mg静推强心治疗,同时使用硝普钠进行扩张血管,氨茶碱静脉输注解痉,并同时进行了导尿治疗。在抢救药物应用过程中,术者在坐位情况时快速缝合术区,加压包扎。经上述治疗后约20分钟,患者呼吸困难明显好转,指尖氧饱和度波动95%~98%,血压心率平稳,转运至监护病房。监护病房经积极有效地抗心衰治疗后患者症状缓解,生命体征平稳,可平卧,肺部啰音消失,4天后平稳出院。

点评:

该患者为器质性心脏病后心功能不全,合并三度房室传导阻滞,心率慢,术前限制了西地兰及β受体阻滞剂等药物的应用。患者术前虽然可平卧,肺部无啰音,但左室射血分数0.34,本身存在潜在的心功能不全。手术时间较长,心脏耐受手术的能力较差,为术中可能发作急性左心心力衰竭埋下隐患。据此,得出以下经验教训。

1.CRT患者需充分做好术前准备:完善各种术前检查,评估心功能状态。对临床症状认真评估,规范心力衰竭药物治疗,术晨测周围静脉压,计数6分钟步行距离,练习床上排尿排便,对于排尿困难者必要时导尿。与患者及家属进行充分的思想沟通、详细的病情分析,使其知情并配合治疗。

2.患者术中平卧位,手术时间持续时间相对较长,对于心力衰竭患者来说此体位会加重胸闷气短症状,持续低流量氧气吸入可以改善患者的缺氧症状;指尖氧饱和度监测可以判断患者的缺氧情况;建立可靠的静脉通路并控制滴速限制入水量;注意观察心电监护情况,警惕室速、室颤的发生,准备除颤仪于备用状态。遇复杂危重情况,果断制定手术策略,争取时间,术中善于利用双导丝技术、鞘中鞘技术等帮助提高手术成功率。加强团队协作,保证手术安全顺利。

3.术后注意事项:术后需卧床20~24小时,心电、血压、指尖氧饱和度监测,术侧肩关节及上肢制动,术区加压包扎,防止出血、血肿及电极移位。术后第2天下床后再次程控相关参数以了解电极导线及起搏器工作状态。

该患者术中发现急性左心心力衰竭比较及时,抢救治疗迅速有效,并立即完成了术区的缝合,避免了术区污染,术后继续给予强化抗心力衰竭治疗,心功能得以明显改善。术后程控起搏器各项参数正常,未发生因为术中抢救中坐起可能带来的电极移位,预后较好,此病例提示对于心力衰竭的患者,CRT手术风险大,手术时间偏长,术前有效地抗心力衰竭治疗至关重要。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1803440, encodeId=75ae180344045, content=<a href='/topic/show?id=a3fce54784c' target=_blank style='color:#2F92EE;'>#突发心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75478, encryptionId=a3fce54784c, topicName=突发心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Thu Nov 01 13:04:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341472, encodeId=89ad13414e2bd, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sat Dec 16 03:04:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517131, encodeId=5df1151e131c8, content=<a href='/topic/show?id=b06f528889' target=_blank style='color:#2F92EE;'>#CRT-D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5288, encryptionId=b06f528889, topicName=CRT-D)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf0c11038551, createdName=minhuang75_72521587, createdTime=Sat Dec 16 03:04:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269335, encodeId=02a9269335d4, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Dec 14 12:07:20 CST 2017, time=2017-12-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1803440, encodeId=75ae180344045, content=<a href='/topic/show?id=a3fce54784c' target=_blank style='color:#2F92EE;'>#突发心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75478, encryptionId=a3fce54784c, topicName=突发心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Thu Nov 01 13:04:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341472, encodeId=89ad13414e2bd, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sat Dec 16 03:04:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517131, encodeId=5df1151e131c8, content=<a href='/topic/show?id=b06f528889' target=_blank style='color:#2F92EE;'>#CRT-D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5288, encryptionId=b06f528889, topicName=CRT-D)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf0c11038551, createdName=minhuang75_72521587, createdTime=Sat Dec 16 03:04:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269335, encodeId=02a9269335d4, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Dec 14 12:07:20 CST 2017, time=2017-12-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1803440, encodeId=75ae180344045, content=<a href='/topic/show?id=a3fce54784c' target=_blank style='color:#2F92EE;'>#突发心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75478, encryptionId=a3fce54784c, topicName=突发心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Thu Nov 01 13:04:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341472, encodeId=89ad13414e2bd, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sat Dec 16 03:04:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517131, encodeId=5df1151e131c8, content=<a href='/topic/show?id=b06f528889' target=_blank style='color:#2F92EE;'>#CRT-D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5288, encryptionId=b06f528889, topicName=CRT-D)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf0c11038551, createdName=minhuang75_72521587, createdTime=Sat Dec 16 03:04:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269335, encodeId=02a9269335d4, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Dec 14 12:07:20 CST 2017, time=2017-12-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1803440, encodeId=75ae180344045, content=<a href='/topic/show?id=a3fce54784c' target=_blank style='color:#2F92EE;'>#突发心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75478, encryptionId=a3fce54784c, topicName=突发心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Thu Nov 01 13:04:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341472, encodeId=89ad13414e2bd, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sat Dec 16 03:04:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517131, encodeId=5df1151e131c8, content=<a href='/topic/show?id=b06f528889' target=_blank style='color:#2F92EE;'>#CRT-D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5288, encryptionId=b06f528889, topicName=CRT-D)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf0c11038551, createdName=minhuang75_72521587, createdTime=Sat Dec 16 03:04:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269335, encodeId=02a9269335d4, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Dec 14 12:07:20 CST 2017, time=2017-12-14, status=1, ipAttribution=)]
    2017-12-14 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

相关资讯

Circulation Ep:心衰患者CRT-D植入后的LVEF与室性心律失常ICD治疗的关系

CRT(cardiac resynchronization therapy)可减轻心衰患者的心衰症状并减少住院次数,改善心衰患者预后。它可以提高一部分患者的左室射血分数(LVEF),在一个小规模的亚组研究中,尽管约25-30%的患者临床改善不明显,但CRT确实可使患者的心室功能接近正常,这部分患者称为超级反应患者(super-responders),其定义为CRT植入后LVEF>=45%。有

ACC 2014:CRT-D可降充血性心衰事件发生率及死亡率

2014年美国心脏病学会年会(ACC 2014)MADIT-CRT研究表明,在QRS波增宽且无症状或有轻微症状(NYHA 分级 I/II)的收缩期充血性心力衰竭(CHF)患者中,心脏再同步治疗除颤器(CRT-D)置入与CHF事件发生率及死亡率显著降低具有相关性。 此项研究共纳入1820例CHF高危患者,并以3:2的比率随机分入CRT-D组或ICD组。利用最新优化技术对CRT房室延搁实施最佳化,以

NEJM:CRT-D有益于合并LBBB轻度心衰患者长期生存(MADIT-CRT)

心脏再同步化治疗多通道自动除颤器植入试验(MADIT-CRT)平均随访2.4年结果表明无症状或有轻微症状心衰合并射血分数减少和QRS延长患者植入CRT-D安全有效,与单纯植入ICD相比,植入CRT-D相对减少34%非致命心衰事件或任何原因导致死亡风险。但CRT-D对于无症状或症状轻微心衰患者长期作用尚不明确。 为此,Goldenberg博士等进一步评估了CRT-D对MADIT-CRT研究纳入人群

李广平:ICD/CRT-P/CRT-D植入指征的变化与临床个体化

一、ICD/CRT-P/CRT-D植入指征的变化 早在2006年中华医学会心电生理与起搏分会《心脏再同步化治疗慢性心力衰竭的建议》和ACC/AHA/HRS 2008年《心脏节律异常器械治疗指南CRT治疗建议》认为,在最佳药物治疗基础上NYHA心功能Ⅰ或Ⅱ级的心衰患者,在植入永久起搏器或ICD时,若预 期需长时期心室起搏可考虑植入CRT,但是仅作为Ⅱb类指征(证据水平:C)。2

Heart:CRT-D未产生额外生存获益

英国一项研究表明,长期随访时心脏再同步治疗除颤器(CRT-D)未能产生额外生存获益。论文于4月1日在线发表于《心脏》(Heart)。 此项研究共纳入500例置入心脏再同步治疗装置的患者,其中置入仅起搏装置(CRT-P)和CRT-D的患者分别为354和146例。随访时间至少为2年,平均随访29个月。主要终点为全因死亡率。 结果显示,共记录116例(23.2%)死亡,CRT-P和CRT-D组分别为

Baidu
map
Baidu
map
Baidu
map